Drugs / Enadenotucirev
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03916510 | Jul 2019 → Feb 2023 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02636036 | Jan 2016 → Oct 2021 | colorectal cancer, head and neck squamous cell carcinoma | Akamis Bio | Completed | No outcome recorded |
| Phase 1 | NCT02028117 | Jun 2014 → Nov 2019 | — | Akamis Bio | Completed | No outcome recorded |
| Phase 1 | NCT02053220 | Jun 2013 → Apr 2015 | colorectal cancer, non-small cell lung carcinoma, renal cell carcinoma, urinary bladder cancer | Akamis Bio | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02028442 | Sep 2012 → Apr 2016 | carcinoma, colorectal cancer, urinary bladder cancer | Akamis Bio | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enadenotucirev | “Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity.” PMID 28923104 ↗ Sep 2017 |
| Known as | ColoAd1 | “Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity.” PMID 28923104 ↗ Sep 2017 |
| Known as | EnAd | “Enadenotucirev (EnAd) is a tumour selective, oncolytic adenovirus which can be given intravenously.” PMID 32532291 ↗ Jun 2020 |
| Route | Intravenous | “administering enadenotucirev intravenously” NCT02028117 ↗ |